Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions highlight the groundbreaking nature of the PROphet test, with contributors describing it as a 'clinical validation' and noting its high potential for guiding personalized lung cancer treatments. The tone is enthusiastic and forward-looking, using words like 'exciting,' 'impactful,' and 'promising,' which reflect a strong consensus on the study’s importance and potential to transform clinical practices.
Most discussions express strong support and enthusiasm for the study’s findings, highlighting its clinical validation and potential for personalized treatment.
Posts consistently show high interest by emphasizing the significance of the research, with phrases like 'exciting news' and 'promising developments,' reflecting curiosity and relevance.
Many contributors reference specific aspects of the publication, such as the clinical validity, biological rationale, and implications for treatment, indicating deep engagement.
The discussions convey a perception that this study could significantly influence future diagnostic and treatment approaches, as evidenced by words like 'paving the way' and 'game changer.'
We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR 2025 we present the biological rationale and function of these proteins. Potential broad therapeutic implications https://t.co/7VMeNYVkHG @isliquidbiopsy https://t.co/iD9cnnbeJu
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
Our recent publication clinically validating PROphet® #NSCLC is now the top feature in @JCOPO_ASCO! If you haven't read it yet, now's the time: https://t.co/8xgLTBb6lx #liquidbiopsy #proteomics #biomarker #precisiononcology @drgandara @APDicker @ChrisDingmanCCO @oferorama https://t.co/sjM11Zd8Pw
https://t.co/XnExsVa3Do
@JCOPO_ASCO has published a study showcasing the clinical validity & utility of PROphet® NSCLC! Thank you to the patients, physicians & scientists who made this milestone possible. We're paving the way for promising developments in #precisiononcology! https://t.co/xS2ElGFYXI https://t.co/x8lm6IEfjB
Dr. Gandara discusses the PROphet blood test that predicts which metastatic NSCLC patients benefit from immunotherapy, aiding personalized treatment decisions beyond current guidelines. The study involved 540 patients…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
RT @drgandara: We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR…
We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. https://t.co/hyF2uRr32l At AACR 2025 we present the biological rationale and function of these proteins. Potential broad therapeutic implications https://t.co/7VMeNYVkHG @isliquidbiopsy https://t.co/iD9cnnbeJu
The metrics of our JCO® Precision Oncology (JCO PO) publication – “Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer” cannot be ignored!
https://t.co/XnExsVa3Do
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
Thrilled to share the impact of our @JCOPO_ASCO paper:
RT @OncoHost: Thank you to Personalized Medicine Coalition (PMC) for featuring OncoHost in their monthly newsletter! Read the peer-reviewe…
Thank you to Personalized Medicine Coalition (PMC) for featuring OncoHost in their monthly newsletter! Read the peer-reviewed paper published in JCO Precision Oncology here: https://t.co/dLU1VuaNYC #NSCLC #personalizedmedicine #lungcancer #proteomics https://t.co/1xWeNZRfuN
RT @OncoHost: Our paper in @JCOPO_ASCO clinically validating our PROphetNSCLC™ test is currently featured content on the journal's website!…
Our paper in @JCOPO_ASCO clinically validating our PROphetNSCLC™ test is currently featured content on the journal's website! Haven't had a chance to read it yet? Now's the time: https://t.co/8xgLTBb6lx #JCO #PrecisionOncology #LungCancerTreatment #LCSM https://t.co/LiW6dD1tc1
RT @OncoHost: Our recent publication clinically validating PROphet® #NSCLC is now the top feature in @JCOPO_ASCO! If you haven't read it…
RT @OncoHost: Our recent publication clinically validating PROphet® #NSCLC is now the top feature in @JCOPO_ASCO! If you haven't read it…
RT @OncoHost: Our recent publication clinically validating PROphet® #NSCLC is now the top feature in @JCOPO_ASCO! If you haven't read it…
Our recent publication clinically validating PROphet® #NSCLC is now the top feature in @JCOPO_ASCO! If you haven't read it yet, now's the time: https://t.co/8xgLTBb6lx #liquidbiopsy #proteomics #biomarker #precisiononcology @drgandara @APDicker @ChrisDingmanCCO @oferorama https://t.co/sjM11Zd8Pw
Thanks to @TheCancerLetter for sharing our exciting news! Read all about our PROphet #NSCLC test's clinical validity and utility in @JCOPO_ASCO here: https://t.co/WmCmtPyBfk https://t.co/Ry0Puhf8Uo
RT @CrozrX: Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic
RT @APDicker: Exciting to be part of a talented multi-disciplinary team to advance the cause for patients with lung cancer https://t.co/gE1…
RT @CrozrX: Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic
RT @CrozrX: Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic
RT @CrozrX: Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic
Exciting to be part of a talented multi-disciplinary team to advance the cause for patients with lung cancer https://t.co/gE1uVeoIu5 @KimmelCancerCtr @TJUHospital @drgandara @NCIDirector
RT @CrozrX: Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic
RT @CrozrX: Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic
RT @OncoHost: @JCOPO_ASCO has published a study showcasing the clinical validity & utility of PROphet® NSCLC! Thank you to the patients, p…
RT @OncoHost: @JCOPO_ASCO has published a study showcasing the clinical validity & utility of PROphet® NSCLC! Thank you to the patients, p…
@JCOPO_ASCO has published a study showcasing the clinical validity & utility of PROphet® NSCLC! Thank you to the patients, physicians & scientists who made this milestone possible. We're paving the way for promising developments in #precisiononcology! https://t.co/xS2ElGFYXI https://t.co/x8lm6IEfjB